Welcome to our dedicated page for Cryo-Cell Intl news (Ticker: CCEL), a resource for investors and traders seeking the latest updates and insights on Cryo-Cell Intl stock.
Cryo-Cell International Inc (CCEL) delivers pioneering solutions in stem cell preservation and cellular therapy research. This dedicated news hub provides investors and industry stakeholders with timely updates on the company’s operational milestones, scientific advancements, and strategic initiatives.
Access verified press releases covering quarterly earnings, regulatory developments, and technology innovations like the PrepaCyte CB processing system. Our curated updates include partnership announcements, clinical trial progress, and market expansion efforts within the $4.7B global cord blood banking sector.
All content undergoes rigorous fact-checking to ensure alignment with SEC filings and corporate communications. Bookmark this page for direct access to Cryo-Cell’s latest achievements in cryogenic storage excellence and regenerative medicine leadership.
Cryo-Cell International (NYSE: CCEL), the world's first private cord blood bank, has reported its fiscal Q1 2025 financial results. The company's revenue increased to $7.97 million from $7.85 million in Q1 2024, primarily consisting of $7.87 million in processing and storage fees.
Net income decreased to $283,000 ($0.03 per share) compared to $556,000 ($0.07 per share) in the same period last year. The company serves over 500,000 parents from 87 countries and operates a public banking program with Duke University that has provided cord blood for more than 600 transplantations.
Cryo-Cell International (CCEL) reported its fiscal year 2024 financial results, showing consolidated revenues of $32.0 million, up from $31.3 million in 2023. The company achieved a net income of $402,000 ($0.05 per share) in 2024, compared to a net loss of $9.5 million in 2023.
The revenue breakdown included $31.6 million in processing and storage fees, $68,000 in product revenue, and $367,000 in public banking revenue. The company faced a $2.4 million income tax expense, with $1.3 million attributed to Florida's revenue apportionment methodology change. Realized and unrealized gains on marketable securities were $1.1 million in 2024, up from $51,000 in 2023.
Cryo-Cell International (NYSE American: CCEL), the world's first private cord blood bank, has announced two significant developments. First, the company's Board of Directors has approved a quarterly cash dividend of $0.25 per share of common stock, payable on February 28, 2025, to shareholders of record as of February 14, 2025. Second, the company has paused its strategic initiatives related to potential sale or merger activities.
The Board will continue to evaluate the dividend policy regularly, though they note there is no guarantee of future dividend payments. Cryo-Cell, which pioneered stem cell separation and storage in 1992, maintains its position as a leader in cord blood banking.
Cryo-Cell International (NYSE: CCEL), the world's first private cord blood bank, has announced the initiation of a regular quarterly cash dividend of $0.25 per share. The dividend will be paid on November 29, 2024, to shareholders of record as of November 15, 2024. The Board of Directors will evaluate the dividend policy regularly, considering factors such as earnings, cash flows, and capital requirements. The company's Chairman and Co-CEO David Portnoy emphasized this as a significant step in delivering shareholder value while continuing to evaluate strategic alternatives.
Cryo-Cell International, Inc. (NYSE: CCEL), the world's first private cord blood bank, reported its fiscal third quarter 2024 financial results. Highlights include:
- Revenue increased to $8.07 million, up from $7.87 million in Q3 2023
- Net income rose to $1.05 million ($0.13 per share), compared to $681,000 ($0.08 per share) in Q3 2023
- Gains on marketable securities were $522,000, up from $93,000 in Q3 2023
The company is exploring strategic alternatives to maximize shareholder value and considering instituting a regular quarterly dividend. Cryo-Cell's proposed spinoff of Celle Corp. is currently on hold due to a Demand for Arbitration filed with Duke University. The company continues to expand its services, including the launch of ExtraVault for biostorage and distribution solutions.
Cryo-Cell International, Inc. (NYSE American: CCEL), the world's first private cord blood bank, reported its fiscal second quarter 2024 financial results. Key highlights include:
- Revenue increased 3% to $8.0 million, compared to $7.8 million in Q2 2023
- Net income rose to $656,000 ($0.08 per share), up from $221,000 ($0.03 per share) in Q2 2023
- Cost of sales decreased by 6%
- Selling, general and administrative expenses decreased by less than 1%
- R&D expenses were $241,000, down from $305,000 in Q2 2023
The company's improved performance was driven by increased processing and storage fee revenue, which offset declines in public banking revenue.
